SML2613
Secnidazole
≥98% (HPLC)
Synonym(s):
1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2ol, 1-(2Hydroxypropyl)-2-methyl-5-nitroimidazole, SYM-1219
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C7H11N3O3
CAS Number:
Molecular Weight:
185.18
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
[N+](=O)([O-])c1[n](c(nc1)C)CC(O)C
InChI
1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
InChI key
KPQZUUQMTUIKBP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
Biochem/physiol Actions
Nitroimidazole antimicrobial
Secnidazole is a nitroimidazole anti-microbial selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. It has been approved for the treatment of bacterial vaginosis. Secnidazole is a prodrug, whose nitro group is reduced by bacterial enzymes to radical anions that interfere with bacterial DNA synthesis.
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Helen S Pentikis et al.
Advances in therapy, 33(12), 2229-2241 (2016-10-17)
Bacterial vaginosis (BV) is a serious infection that is the most common vaginal infection in women of childbearing potential. SYM-1219 is a novel, granule formulation containing 2 g of secnidazole that is being developed as a single, oral dose to treat
Melinda A B Petrina et al.
Anaerobe, 47, 115-119 (2017-05-20)
Secnidazole, a 5-nitroimidazole with a longer half-life, is structurally related to metronidazole and tinidazole. For treatment of bacterial vaginosis (BV), secnidazole is a suitable single-dose oral drug having a longer serum half-life than metronidazole. The objective of this study was
Borje Darpo et al.
Journal of clinical pharmacology, 58(3), 286-293 (2017-10-03)
SYM-1219, a novel oral granule formulation of secnidazole, is under development as single-dose treatment for bacterial vaginosis. This 4-way, randomized, crossover study evaluated the effects of SYM-1219 on electrocardiographic (ECG) parameters in 52 healthy subjects. Subjects were administered single doses
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service